Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
Buy | Overweight | Hold | Underweight | Sell |
---|---|---|---|---|
4 | 0 | 0 | 0 | 0 |
Analyst Firms Making Recommendations1
- Wells Fargo
- Oppenheimer
- Keefe, Bruyette & Woods
- Raymond James
- B of A Securities
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Crescent Capital BDC
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
11/13/2023 | CCAP | Buy Now | Crescent Capital BDC | $16.68 | -4.11% | Wells Fargo | Finian O'Shea | $16.5 → $16 | Downgrade | Overweight → Equal-Weight | Get Alert |
05/16/2023 | CCAP | Buy Now | Crescent Capital BDC | $16.68 | 7.88% | Oppenheimer | Mitchel Penn | → $18 | Reiterates | Outperform → Outperform | Get Alert |
04/11/2023 | CCAP | Buy Now | Crescent Capital BDC | $16.68 | 7.88% | Keefe, Bruyette & Woods | Ryan Lynch | → $18 | Initiates | → Outperform | Get Alert |
02/24/2023 | CCAP | Buy Now | Crescent Capital BDC | $16.68 | 7.88% | Oppenheimer | Mitchel Penn | $19 → $18 | Maintains | Outperform | Get Alert |
10/05/2022 | CCAP | Buy Now | Crescent Capital BDC | $16.68 | 7.88% | Raymond James | Robert Dodd | $20.5 → $18 | Maintains | Outperform | Get Alert |
08/12/2022 | CCAP | Buy Now | Crescent Capital BDC | $16.68 | 13.87% | Oppenheimer | Mitchel Penn | $20 → $19 | Upgrade | Perform → Outperform | Get Alert |
08/12/2022 | CCAP | Buy Now | Crescent Capital BDC | $16.68 | 22.86% | Raymond James | Robert Dodd | $21 → $20.5 | Maintains | Outperform | Get Alert |
05/11/2022 | CCAP | Buy Now | Crescent Capital BDC | $16.68 | 7.88% | Wells Fargo | Finian O'Shea | $18.5 → $18 | Maintains | Overweight | Get Alert |
04/25/2022 | CCAP | Buy Now | Crescent Capital BDC | $16.68 | 10.88% | Wells Fargo | Finian O'Shea | $19.5 → $18.5 | Maintains | Overweight | Get Alert |
01/31/2022 | CCAP | Buy Now | Crescent Capital BDC | $16.68 | 16.87% | B of A Securities | Derek Hewett | → $19.5 | Initiates | → Buy | Get Alert |
11/12/2021 | CCAP | Buy Now | Crescent Capital BDC | $16.68 | 28.86% | Raymond James | Robert Dodd | — | Maintains | Outperform | Get Alert |
07/16/2021 | CCAP | Buy Now | Crescent Capital BDC | $16.68 | — | Oppenheimer | — | — | Initiates | → Perform | Get Alert |
What is the target price for Crescent Capital BDC (CCAP)?
The latest price target for Crescent Capital BDC (NASDAQ: CCAP) was reported by Wells Fargo on November 13, 2023. The analyst firm set a price target for $16.00 expecting CCAP to fall to within 12 months (a possible -4.11% downside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Crescent Capital BDC (CCAP)?
The latest analyst rating for Crescent Capital BDC (NASDAQ: CCAP) was provided by Wells Fargo, and Crescent Capital BDC downgraded their equal-weight rating.
When is the next analyst rating going to be posted or updated for Crescent Capital BDC (CCAP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Crescent Capital BDC, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Crescent Capital BDC was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
Is the Analyst Rating Crescent Capital BDC (CCAP) correct?
While ratings are subjective and will change, the latest Crescent Capital BDC (CCAP) rating was a downgraded with a price target of $16.50 to $16.00. The current price Crescent Capital BDC (CCAP) is trading at is $16.68, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.